Le Lézard
Classified in: Health
Subject: AWD

PharmaCielo Awarded Game-Changer Award by MJDaily


TORONTO and RIONEGRO, Colombia, Dec. 14, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., has been recognized with the prestigious MJ Biz Daily Game-Changer Award for the Latin America Region. The inaugural award was presented to the Company at a special gala, part of the MJ Biz Conference in Las Vegas, the world's largest cannabis conference and tradeshow. The award program recognizes global leaders, both companies and individuals, for their excellence and impact on the hemp and cannabis industries.

PharmaCielo (CNW Group/PharmaCielo Ltd.)

"We are tremendously honoured to receive this award, but even more thrilled that the panel of judges recognized PharmaCielo's role and contribution in paving the way and building the medical cannabis industry in Latin America," said David Attard, Chief Executive Officer, PharmaCielo Ltd. "Being an industry trailblazer is a challenging task. It means that whatever we do, every step of progress achieved, is a first for the industry, with the rule book written as we go. Now that we have laid the groundwork we are looking forward to a strong 2020 and expanding our existing presence throughout Latin America which began with Mexico, and which in 2019 added a number of others including both Uruguay and Argentina. This achievement is dedicated to PharmaCielo's employees who made this happen and who continue to maintain PharmaCielo and Colombia's positions as top players on the cannabis world stage."

About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

SOURCE PharmaCielo Ltd.


These press releases may also interest you

at 02:30
PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc announce that the waiting period under the Hart-Scott-Rodino Antitrust...

at 02:30
FSD Pharma Inc.   (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma's...

at 02:21
Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and...

at 02:20
Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update,...

at 02:14
Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that Eddy Cojulun joined Envirotainer as the new Chief Sales Officer (CSO) in December 2019. In his new role Eddy will report...

at 02:13
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the EMA Paediatric Committee (PDCO) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) for Nefecon for the treatment of primary IgA nephropathy (IgAN). With...



News published on 14 december 2019 at 10:38 and distributed by: